Abstract
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major clinical problem since it is the dose-limiting side effect of a significant number of antineoplastic drugs. The incidence of CIPN varies depending on the conditions, but severe neuropathy can occur in up to 40% of patients undergoing a polichemotherapy regimen. Moreover, even when CIPN is not a dose-limiting side effect, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. Currently, no treatment is available which can significantly improve the clinical signs and symptoms of CIPN. In recent years, new agents have been proposed as neuroprotectants, and some of them have been more specifically studied for CIPN. So far, the most interesting results for future applications have been obtained in the pre-clinical studies involving cytokines and growth factors. For several of these drugs, in fact, sound hypotheses have been formulated to support the idea of a protective role on selected neuronal targets. However, this theoretical basis has frequently failed to lead to consistent results in pre-clinical and clinical applications. We will review the state-of-the-art of CIPN treatment with growth factors and focus on the future prospects opened up by the most recent pre-clinical and clinical studies.
Keywords: Chemotherapy, peripheral neuropathy, neurotoxicity, neuroprotection, growth factors
Current Drug Safety
Title: The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity
Volume: 1 Issue: 1
Author(s): Guido Cavaletti and Paola Marmiroli
Affiliation:
Keywords: Chemotherapy, peripheral neuropathy, neurotoxicity, neuroprotection, growth factors
Abstract: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major clinical problem since it is the dose-limiting side effect of a significant number of antineoplastic drugs. The incidence of CIPN varies depending on the conditions, but severe neuropathy can occur in up to 40% of patients undergoing a polichemotherapy regimen. Moreover, even when CIPN is not a dose-limiting side effect, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. Currently, no treatment is available which can significantly improve the clinical signs and symptoms of CIPN. In recent years, new agents have been proposed as neuroprotectants, and some of them have been more specifically studied for CIPN. So far, the most interesting results for future applications have been obtained in the pre-clinical studies involving cytokines and growth factors. For several of these drugs, in fact, sound hypotheses have been formulated to support the idea of a protective role on selected neuronal targets. However, this theoretical basis has frequently failed to lead to consistent results in pre-clinical and clinical applications. We will review the state-of-the-art of CIPN treatment with growth factors and focus on the future prospects opened up by the most recent pre-clinical and clinical studies.
Export Options
About this article
Cite this article as:
Cavaletti Guido and Marmiroli Paola, The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity, Current Drug Safety 2006; 1 (1) . https://dx.doi.org/10.2174/157488606775252656
DOI https://dx.doi.org/10.2174/157488606775252656 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TakoTsubo Cardiomyopathy A Short Review
Current Cardiology Reviews Physiological Significance and Therapeutic Potential of Adrenomedullin in Pulmonary Hypertension
Cardiovascular & Hematological Disorders-Drug Targets Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Current Pharmaceutical Design HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Cardioprotective Effects of the I<sub>f</sub> Current Inhibition by Ivabradine During Cardiac Dysfunction
Current Pharmaceutical Biotechnology Synthesis and Spectral Study of Some Novel Oxime Esters Derived from 3-azabicyclo[3.3.1]nonan-9-one Oxime
Letters in Organic Chemistry Molecular Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Hemodialysis Patients
Current Signal Transduction Therapy Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Novel Antiinflammatory and Antiinfective Agents
Anti-Infective Agents in Medicinal Chemistry Pharmacological Properties and Therapeutic Possibilities for Drugs Acting Upon Endocannabinoid Receptors
Current Drug Targets - CNS & Neurological Disorders QT Alterations in Psychopharmacology: Proven Candidates and Suspects
Current Drug Safety Potential Mechanisms of Failure in the Sudden Infant Death Syndrome
Current Pediatric Reviews Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Neurotensin NTS1-Dopamine D2 Receptor-Receptor Interactions in Putative Receptor Heteromers: Relevance for Parkinson`s Disease and Schizophrenia
Current Protein & Peptide Science Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued)